An interventional study of Neuropixel probe recording in Glioma, Glioblastoma (GBM) and Brain Tumor-Glioma, sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Glioblastoma with a site in Netherlands — 24 open to participants now, 33 under way, 5 of them phase 3. Glioblastoma · Netherlands.
Among the 92 studies in Glioblastoma with a site in Netherlands, this one is the 59th largest by planned enrollment of the 77 interventional ones that give a count, is one of 2 that started in 2026, is one of 15 with no phase, reaches primary completion later than 32 of the 32 other live ones, and was the 87th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →24 of the 92 studies in Glioblastoma with a site in Netherlands are open now. Recruiting first, the newest first:
Telix Pharmaceuticals (Innovations) Pty Limited · Sites in Netherlands, Australia, Austria and 1 more country
Ages 18+
Nationwide Children's Hospital · Sites in Netherlands, United States, Australia and 3 more countries
Ages 1–21 · Healthy volunteers
Bayer · Sites in Netherlands, United States, Australia and 10 more countries
Ages 18+
Rigel Pharmaceuticals · Sites in Netherlands, United States, Australia and 4 more countries
Ages 12–39
Erasmus Medical Center · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 24 · Phase 3 18 · Phase 4 1
First in 1999; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 76 across the 77 interventional studies, 325 across the 15 observational. Of the 53 that completed or were terminated, 18 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 92 have an industry lead sponsor. The 10 most frequent:
Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Erasmus Medical Center has 8 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
10 of the studies in Glioblastoma with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05904119Phase 3European Organisation for Research and Treatment of Cancer - EORTCLomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study | 2027-09 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT07121842Erasmus Medical CenterGlioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI | 2027-01 |
| NCT04868396Maastricht Radiation OncologyPatient-derived Glioma Stem Cell Organoids | 2027-01-01 |
| NCT05641220Erasmus Medical CenterBiopsy Versus Resection in Elderly Glioblastoma Patients. A Prospective Cohort Study. | 2027-01-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 92 studies in Glioblastoma with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
INTRODUCTION AND RATIONALE
Aggressive brain tumors like glioma have the ability to infiltrate the surrounding healthy brain tissue, disrupting normal neuronal activities and leading to impaired motor and cognitive functions, as well as causing epilepsy. This malignant brain tumor is considered one of the most challenging cancers to treat, with a median survival of 12 to 15 months. Recent findings on direct neuron-tumor interactions indicate that abnormal brain activity in the regions surrounding brain tumours may contribute to develop epilepsy and accelerating tumor growth. Tumors tend to 'fuel' themselves with neurotransmitters released during its 'daily' neuronal firing. Hyperactive neurons in the peritumoral cortex can form excitatory electrochemical synapses with surrounding tumor cells, creating direct communication pathways within the peritumoral microenvironment, which aids in the progression and proliferation of tumor cells via direct and paracrine signalling pathways. However, the specific features of this abnormal brain activity in the peritumoral cortex have not been fully clarified and information on the pathological changes of neuronal activity in glioma patients is largely lacking. To advance more effective treatment strategies, it is crucial to better understand the complex interactions between the tumor and the brain.
This is especially important for our group of patients of which many perceive diminished quality of life because of epilepsy, cognitive functioning and language problems after tumor surgery. Furthermore, we lack thorough understanding of what tumor resection does to the original hyperactive peritumoral cortex and if resecting this is beneficial for improving postoperative outcome both for epilepsy as well as regarding survival. Therefore, identifying the hyperactive peritumoral cortex and directly addressing its impacts on the brain function and long-term surgical outcome could be a promising novel therapeutic strategy for treating glioma patients.
STUDY AIM
Our measurement focuses on capturing neuronal activity at single-neuron resolution in the peritumoral cortex of glioma patients using cortical depth electrodes. It is well-established that gliomas can remodel the surrounding brain tissue, leading to abnormal neuronal hyperactivity, which contributes to tumor progression and epilepsy. However, the specific neuronal patterns and underlying mechanisms of these changes are not yet fully understood. Our study will aim to collect detailed single-neuron recordings in this context, enabling us to map the precise neurophysiological disruptions caused by gliomas. On the long term, our research could lay the groundwork in identifying novel therapeutic approaches by providing critical in-sights into how gliomas alter brain function.
In this study, patients with a brain tumour who undergo (awake) surgical resection as part of standard clinical care will be included. All patients who undergo such a procedure at Erasmus MC within a five-year period will be invited to participate. Based on historical case numbers, we aim to include ten patients with successful recordings during this timeframe.
The surgical procedure itself will be performed entirely according to standard clinical protocols; the surgery is not part of the research intervention. Neurological functioning will be assessed pre- and postoperatively as part of routine care. Participation in the study concludes at the end of the surgical procedure. All other procedures outside the research recordings are likewise performed within standard care.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
This study's planned enrollment of 20 is below the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Browse Glioblastoma studies →Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Compared within Glioblastoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glioma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The criteria were revised on the registry on Oct 5, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cortical electrophysiology using the Neuropixel probe is performed to record brain activity in the peritumoral cortex
Device: Neuropixel probe recording
Neuropixel recordings captures neuronal activity at the single-neuron level across the layers of the cortex.
Also known as: laminar electrophysiology, cortical depth electrophysiology
Number of Participants With a Successful Intraoperative Neuropixels Probe Recording
Feasibility is reported as the number (and percentage) of enrolled participants in whom a successful Neuropixels probe recording is obtained. A recording is counted as successful when (1) the probe is inserted into the peritumoral cortex as planned, (2) neural data are acquired during surgery with at least one isolated single neuron after spike sorting, and (3) no device-related complications occur (retained probe fragments, infection, or hemorrhage). Reasons for unsuccessful recordings are documented in the case report form.
Time frame: From the beginning of surgery until hospital discharge
Number of Isolated Single Neurons per Participant Recorded in Peritumoral Cortex
To assess whether intraoperative single-cell recordings are suitable for identifying prognostic biomarkers of disease progression, the number of single neurons isolated per participant is counted after spike sorting of the Neuropixels data. Only units that meet the predefined spike-sorting quality criteria are counted. Results are summarized as median (range) across participants. For each isolated neuron, the firing rate (spikes per second) and waveform characteristics are also reported descriptively.
Time frame: From the beginning to end of surgery
Plan to share: Undecided
Started Jan 2026 (actual). Primary completion is estimated for Jan 2030, 48 months after the start.
Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 48 months is below that.
Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start Dec 2025 → Jan 2026, primary completion Jun 2029 → Jan 2030 and completion Jun 2029 → Jan 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.